- Home
- BCAB vs NRXS Comparison
BCAB vs NRXS Comparison
Compare BCAB & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- NRXS
- Stock Information
- Founded
- BCAB 2007
- NRXS 2011
- Country
- BCAB United States
- NRXS United States
- Employees
- BCAB N/A
- NRXS N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- NRXS
- Sector
- BCAB Health Care
- NRXS
- Exchange
- BCAB Nasdaq
- NRXS Nasdaq
- Market Cap
- BCAB 31.5M
- NRXS 25.8M
- IPO Year
- BCAB 2020
- NRXS 2023
- Fundamental
- Price
- BCAB $0.79
- NRXS $3.00
- Analyst Decision
- BCAB Hold
- NRXS Strong Buy
- Analyst Count
- BCAB 3
- NRXS 1
- Target Price
- BCAB $1.00
- NRXS $7.00
- AVG Volume (30 Days)
- BCAB 953.7K
- NRXS 55.1K
- Earning Date
- BCAB 11-06-2025
- NRXS 11-11-2025
- Dividend Yield
- BCAB N/A
- NRXS N/A
- EPS Growth
- BCAB N/A
- NRXS N/A
- EPS
- BCAB N/A
- NRXS N/A
- Revenue
- BCAB $11,000,000.00
- NRXS $3,217,531.00
- Revenue This Year
- BCAB N/A
- NRXS $62.14
- Revenue Next Year
- BCAB N/A
- NRXS $131.87
- P/E Ratio
- BCAB N/A
- NRXS N/A
- Revenue Growth
- BCAB N/A
- NRXS 41.93
- 52 Week Low
- BCAB $0.24
- NRXS $1.33
- 52 Week High
- BCAB $2.53
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- BCAB 66.59
- NRXS 60.01
- Support Level
- BCAB $0.63
- NRXS $2.98
- Resistance Level
- BCAB $0.89
- NRXS $3.24
- Average True Range (ATR)
- BCAB 0.07
- NRXS 0.17
- MACD
- BCAB 0.00
- NRXS 0.03
- Stochastic Oscillator
- BCAB 70.47
- NRXS 67.50
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).